Literature DB >> 21055812

Preoperative intravitreal bevacizumab use as an adjuvant to diabetic vitrectomy: histopathologic findings and clinical implications.

Hazem A El-Sabagh1, Walid Abdelghaffar, Ahmad M Labib, Carlos Mateo, Tarek M Hashem, Dalal M Al-Tamimi, Abdulhafez A Selim.   

Abstract

PURPOSE: To evaluate the effects of intervals between preoperative intravitreal injection of bevacizumab (IVB) and surgery on the components of removed diabetic fibrovascular proliferative membranes.
DESIGN: Interventional, consecutive, prospective, comparative case series. PARTICIPANTS: A total of 52 eyes of 49 patients with active diabetic fibrovascular proliferation with complications necessitating vitrectomy.
METHODS: Participant eyes that had IVB were divided into 8 groups in which vitreoretinal surgery was performed at days 1, 3, 5, 7, 10, 15, 20, and 30 postinjection. A group of eyes with the same diagnosis and surgical intervention without IVB injection was used for comparison. In all eyes, proliferative membrane specimens obtained during vitrectomy were sent for histopathologic examination using hematoxylin-eosin stain, immunohistochemistry (CD34 and smooth muscle actin), and Masson's trichrome stain. MAIN OUTCOME MEASURES: Comparative analysis of different components of the fibrovascular proliferation (CD34, smooth muscle actin, and collagen) among the study groups.
RESULTS: Pan-endothelial marker CD34 expression levels starting from day 5 postinjection were significantly less than in the control group (P < 0.001), with minimum expression (1+) in all specimens removed at or after day 30 postinjection. Positive staining for smooth muscle actin was barely detected in the control eyes at day 1, and consistently intense at day 15 and beyond (P < 0.001). The expression level of trichrome staining was significantly high at day 10, compared with control eyes (P < 0.001), and continued to increase at subsequent surgical time points.
CONCLUSIONS: A profibrotic switch was observed in diabetic fibrovascular proliferation after IVB, and our results suggest that at approximately 10 days post-IVB the vascular component of proliferation is markedly reduced, whereas the contractile components (smooth muscle actin and collagen) are not yet abundant.
Copyright © 2011 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21055812     DOI: 10.1016/j.ophtha.2010.08.038

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  24 in total

1.  OCT angiography-based monitoring of neovascular regression on fibrovascular membrane after preoperative intravitreal conbercept injection.

Authors:  Zizhong Hu; Yun Su; Ping Xie; Lu Chen; Jiangdong Ji; Ting Feng; Shaowei Wu; Kang Liang; Qinghuai Liu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-05-03       Impact factor: 3.117

2.  Modulating EGFR-MTORC1-autophagy as a potential therapy for persistent fetal vasculature (PFV) disease.

Authors:  Meysam Yazdankhah; Peng Shang; Sayan Ghosh; Imran A Bhutto; Nadezda Stepicheva; Rhonda Grebe; Stacey Hose; Joseph Weiss; Tianqi Luo; Subrata Mishra; S Amer Riazuddin; Arkasubhra Ghosh; James T Handa; Gerard A Lutty; J Samuel Zigler; Debasish Sinha
Journal:  Autophagy       Date:  2019-09-01       Impact factor: 16.016

3.  Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab.

Authors:  Jiu-Ke Li; Fang Wei; Xiao-Hong Jin; Yuan-Min Dai; Hu-Shan Cui; Yu-Min Li
Journal:  Int J Ophthalmol       Date:  2015-12-18       Impact factor: 1.779

4.  Six-month visual outcome after pars plana vitrectomy in proliferative diabetic retinopathy with or without a single preoperative injection of intravitreal bevacizumab.

Authors:  Amod Gupta; Reema Bansal; Vishali Gupta; Mangat R Dogra
Journal:  Int Ophthalmol       Date:  2012-03-27       Impact factor: 2.031

5.  Correlation of macular thickness and posterior hyaloid change following bevacizumab and triamcinolone in diffuse diabetic macular edema in middle-aged patients.

Authors:  Sambuddha Ghosh; Jayanta Dutta; Subhalakshmi Mukhopadhyay; Gautam Bhaduri
Journal:  Int Ophthalmol       Date:  2011-10-07       Impact factor: 2.031

6.  Comparison of before versus after intravitreal bevacizumab injection, growth factor levels and fibrotic markers in vitreous samples from patients with proliferative diabetic retinopathy.

Authors:  Fevzi Ozer; Ecem Onder Tokuc; Merve Gulsen Bal Albayrak; Gurler Akpinar; Murat Kasap; Veysel Levent Karabas
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-01-14       Impact factor: 3.117

Review 7.  [VEGF inhibitors in vitreoretinal interventions].

Authors:  N Feltgen; A Stahl
Journal:  Ophthalmologe       Date:  2013-10       Impact factor: 1.059

8.  APOPTOSIS AND ANGIOFIBROSIS IN DIABETIC TRACTIONAL MEMBRANES AFTER VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITION: Results of a Prospective Trial. Report No. 2.

Authors:  Chunhua Jiao; Dean Eliott; Christine Spee; Shikun He; Kai Wang; Robert F Mullins; David R Hinton; Elliott H Sohn
Journal:  Retina       Date:  2019-02       Impact factor: 4.256

9.  Effect of intravitreal conbercept treatment before vitrectomy in proliferative diabetic retinopathy.

Authors:  Jian-Bo Mao; Han-Fei Wu; Yi-Qi Chen; Shi-Xin Zhao; Ji-Wei Tao; Yun Zhang; Bin Zheng; Lin Wang; Li-Jun Shen
Journal:  Int J Ophthalmol       Date:  2018-07-18       Impact factor: 1.779

Review 10.  Research progress on the role of connective tissue growth factor in fibrosis of diabetic retinopathy.

Authors:  Teng Ma; Li-Jie Dong; Xue-Li Du; Rui Niu; Bo-Jie Hu
Journal:  Int J Ophthalmol       Date:  2018-09-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.